Table of Content

1 Key Insights

2 Report Introduction

3 ESR1 Mutated Metastatic Breast Cancer Market Overview at a Glance
3.1 Market Share (%) Distribution of ESR1 Mutated metastatic breast cancer by Therapies (First-line) in 2018
3.2 Market Share (%) Distribution of ESR1 Mutated metastatic breast cancer by Therapies (Second-line Plus) in 2018
3.3 Market Share (%) Distribution of ESR1 Mutated metastatic breast cancer by Therapies (First-line) in 2030
3.4 Market Share (%) Distribution of ESR1 Mutated metastatic breast cancer by Therapies (Second-line Plus) in 2030

4 ESR1 Mutated Metastatic Breast Cancer Market: Future Perspective

5 Executive Summary of ESR1 Mutated Metastatic Breast Cancer

6 Key Events

7 Disease Background and Overview
7.1 Introduction
7.2 ESR1 Mutations
7.2.1 The Spectrum of ESR1 Alterations is found in Metastatic ER+ Breast Cancer
7.2.2 Subgroups at Increased Risk of Developing ESR1 Mutations
7.3 Endocrine therapy
7.3.1 Mechanisms of Endocrine Therapy Resistance
7.4 Diagnosis
7.5 Treatment and Management

8 Epidemiology and Patient Population
8.1 Key Findings
8.2 Methodology of Epidemiology
8.3 Epidemiology Assumptions and Rationale
8.4 Total Diagnosed Prevalent Cases of HR Positive Breast Cancer in the 7MM
8.5 Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the 7MM
8.5.1 Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the First Line in the 7MM
8.5.2 Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the Second Line plus in the 7MM
8.6 United States
8.6.1 Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in the United States
8.6.2 Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the United States
8.6.3 Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in the United States
8.7 EU-5
8.7.1 Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in the EU-5
8.7.2 Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the EU-5
8.7.3 Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in the EU-5
8.8 Japan
8.8.1 Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in Japan
8.8.2 Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in Japan
8.8.3 Diagnosed Prevalent Cases of ESR1 Mutation Metastatic Breast Cancer in Japan

9 Patient Journey

10 Organizations contributing towards ESR1 Mutated Metastatic Breast Cancer

11 Emerging Drugs
11.1 Key Cross Competition
11.2 Elacestrant (RAD1901): Radius Pharmaceuticals/Berlin-Chemie (Menarini Group)
11.2.1 Product Description
11.2.2 Other Developmental Activities
11.2.3 Clinical Development
11.2.4 Clinical Trials Information
11.2.5 Safety and Efficacy
11.2.6 Product Profile
11.2.7 Analysts’ Views
11.3 Ibrance (Palbociclib): Pfizer
11.3.1 Drug Description
11.3.2 Other Developmental Activities
11.3.3 Clinical Development
11.3.4 Clinical Trials Information
11.3.5 Safety and Efficacy
11.3.6 Product Profile
11.4 Amcenestrant (SAR439859): Sanofi
11.4.1 Product Description
11.4.2 Other Developmental Activities
11.4.3 Clinical Development
11.4.4 Clinical Trials Information
11.4.5 Safety and Efficacy
11.4.6 Product Profile
11.4.7 Analysts’ Views
11.5 Rintodestrant (G1T48): G1 Therapeutics, Inc.
11.5.1 Product Description
11.5.2 Other Developmental Activities
11.5.3 Clinical Development
11.5.4 Clinical Trials Information
11.5.5 Safety and Efficacy
11.5.6 Product Profile
11.5.7 Analysts’ Views
11.6 SCO-120: Sun Pharma Advanced Research Company
11.6.1 Drug Description
11.6.2 Clinical Development
11.6.3 Clinical Trials Information
11.6.4 Product Profile
11.7 ZB716: Zenopharm
11.7.1 Drug Description
11.7.2 Clinical Development
11.7.3 Clinical Trials Information
11.7.4 Product Profile
11.8 ARV-471: Arvinas
11.8.1 Drug Description
11.8.2 Other Developmental Activities
11.8.3 Clinical Development
11.8.4 Clinical Trials Information
11.8.5 Safety and Efficacy
11.8.6 Product Profile
11.9 Lasofoxifene: Sermonix Pharmaceuticals
11.9.1 Product Description
11.9.2 Other Developmental Activities
11.9.3 Clinical Development
11.9.4 Clinical Trials Information
11.9.5 Product Profile
11.9.6 Analysts’ Views
11.10 H3B-6545: H3 Biomedicine/ Eisai
11.10.1 Product Description
11.10.2 Other Developmental Activities
11.10.3 Clinical Development
11.10.4 Clinical Trials Information
11.10.5 Safety and Efficacy
11.10.6 Product Profile
11.11 Giredestrant (RG6171, GDC-9545): Roche
11.11.1 Product Description
11.11.2 Clinical Development
11.11.3 Clinical Trials Information
11.11.4 Safety and Efficacy
11.11.5 Product Profile
11.11.6 Analysts’ Views
11.12 Camizestrant (AZD9833): AstraZeneca
11.12.1 Product Description
11.12.2 Other Developmental Activities
11.12.3 Clinical Development
11.12.4 Clinical Trials Information
11.12.5 Safety and Efficacy
11.12.6 Product Profile
11.13 LSZ102: Novartis
11.13.1 Product Description
11.13.2 Other Developmental Activities
11.13.3 Clinical Development
11.13.4 Clinical Trials Information
11.13.5 Safety and Efficacy
11.13.6 Product Profile
11.14 ZN-c5: Zentalis Pharmaceuticals
11.14.1 Product Description
11.14.2 Other Developmental Activities
11.14.3 Clinical Development
11.14.4 Clinical Trials Information
11.14.5 Safety and Efficacy
11.14.6 Product Profile
11.15 OP1250: Olema Pharmaceuticals
11.15.1 Product Description
11.15.2 Other Developmental Activities
11.15.3 Clinical Development
11.15.4 Clinical Trials Information
11.15.5 Product Profile

12 ESR1 Mutated Metastatic Breast Cancer: Seven Major Market Analysis
12.1 Key Findings
12.2 Market Methodology
12.3 Market Size of ESR1 Mutated Metastatic Breast Cancer in the 7MM
12.4 Market Size by Therapies of ESR1 Mutated Metastatic Breast Cancer in the 7MM
12.4.1.1 Market Size of ESR1 Mutated Metastatic Breast Cancer by First-line of Therapies
12.4.1.2 Market Size of ESR1 Mutated Metastatic Breast Cancer by Second-line plus of Therapies
12.5 Potential of Emerging and Current Therapies
12.6 Key Market Forecast Assumptions
12.7 Attribute Analysis
12.8 Market Outlook
12.9 Market Size of ESR1 Mutated Metastatic Breast Cancer in the United States
12.9.1 Total Market Size of ESR1 Mutated Metastatic Breast Cancer
12.9.2 Market Size by Therapies of ESR1 Mutated Metastatic Breast Cancer
12.9.2.1 Market Size of ESR1 Mutated Metastatic Breast Cancer by First-line of Therapies
12.9.2.2 Market Size of ESR1 Mutated Metastatic Breast Cancer by Second-line plus of Therapies
12.10 Market Size of ESR1 Mutated Metastatic Breast Cancer in the EU5
12.10.1 Total Market Size of ESR1 Mutated Metastatic Breast Cancer
12.10.2 Market Size by Therapies of ESR1 Mutated Metastatic Breast Cancer
12.10.2.1 Market Size of ESR1 Mutated Metastatic Breast Cancer by First-line of Therapies
12.10.2.2 Market Size of ESR1 Mutated Metastatic Breast Cancer by Second-line Plus of Therapies
12.11 Market Size of ESR1 Mutated Metastatic Breast Cancer in Japan
12.11.1 Total Market Size of ESR1-Mutated Metastatic Breast Cancer
12.11.2 Market Size by Therapies of ESR1 Mutated Metastatic Breast Cancer
12.11.2.1 Market Size of ESR1 Mutated Metastatic Breast Cancer by First-line of Therapies
12.11.2.2 Market Size of ESR1 Mutated Metastatic Breast Cancer by Second-line Plus of Therapies
13 KOL Views
14 Market Drivers
15 Market Barriers
16 SWOT Analysis
17 Unmet Needs
18 Reimbursement and Market Access
19 Appendix
19.1 Bibliography
19.2 Report Methodology
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight



List of Figures

Figure 1 Location of ESR1 Missense Mutations Found in Clinical Samples
Figure 2 The Spectrum of ESR1 Alterations is found in Metastatic ER+ Breast Cancer
Figure 3 Schematic Representation of Identification of ESR1 Mutations in Metastatic Breast Cancer
Figure 4 Diagrammatic Representation of Known Mechanisms of Resistance to Endocrine Therapy
Figure 5 Endocrine Resistance Mechanisms and Altered ER Functions In Breast Cancer and Novel Therapeutic Strategies
Figure 6 Diagnosis of ESR1 Mutation
Figure 7 Targetable Pathways in ESR1-mutant Cells Identified in Preclinical Studies
Figure 8 Total Diagnosed Prevalent Cases of HR Positive Breast Cancer in the 7MM, in Thousand (2018–2030)
Figure 9 Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the 7MM, in Thousand (2018–2030)
Figure 10 Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the First Line in the 7MM, in Thousand (2018–2030)
Figure 11 Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the Second Line plus in the 7MM, in Thousand (2018–2030)
Figure 12 Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in the United States, in Thousand (2018–2030)
Figure 13 Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the United States, in Thousand (2018–2030)
Figure 14 Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in the US, in Thousand (2018–2030)
Figure 15 Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in the EU-5, in Thousand (2018–2030)
Figure 16 Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the EU-5, in Thousand (2018–2030)
Figure 17 Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in the EU-5, in Thousand (2018–2030)
Figure 18 Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in Japan, in Thousand (2018–2030)
Figure 19 Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in Japan, in Thousand (2018–2030)
Figure 20 Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in Japan, in Thousand (2018–2030)
Figure 21 Patient Journey
Figure 22 Market Size of ESR1 Mutated Metastatic Breast Cancer in the 7MM in USD Million (2018–2030)
Figure 23 Market Size of ESR1 Mutated Metastatic Breast Cancer by First-line of Therapies in the 7MM, in USD Million (2018–2030)
Figure 24 Market Size of ESR1 Mutated Metastatic Breast Cancer by Second-line Plus of Therapies in the 7MM, in USD Million (2018–2030)
Figure 25 Market Size of ESR1 Mutated Metastatic Breast Cancer in the United States, in USD Millions (2018–2030)
Figure 26 Market Size of ESR1 Mutated Metastatic Breast Cancer by First-line of Therapies in the US, in USD Million (2018–2030)
Figure 27 Market Size of ESR1 Mutated Metastatic Breast Cancer by Second-line Plus of Therapies in the US, in USD Million (2018–2030)
Figure 28 Market Size of ESR1 Mutated Metastatic Breast Cancer in the EU5, USD Millions (2018–2030)
Figure 29 Market Size of ESR1 Mutated Metastatic Breast Cancer by First-line of Therapies in the EU5, in USD Million (2018–2030)
Figure 30 Market Size of ESR1 Mutated Metastatic Breast Cancer by Second-line Plus of Therapies in the EU5, in USD Million (2018–2030)
Figure 31 Market Size of ESR1 Mutated Metastatic Breast Cancer in Japan, in USD Millions (2018–2030)
Figure 32 Market Size of ESR1 Mutated Metastatic Breast Cancer by First-line of Therapies in Japan, in USD Million (2018–2030)
Figure 33 Market Size of ESR1 Mutated Metastatic Breast Cancer by Second-line Plus of Therapies in Japan, in USD Million (2018–2030)
Figure 34 Market Drivers
Figure 35 Market Barriers
Figure 36 SWOT Analysis
Figure 37 Unmet Needs

List of Tables

Table 1 Summary of ESR1 Mutated Metastatic Breast Cancer, Market and Epidemiology (2018–2030)
Table 2 Key Events
Table 3 Total Diagnosed Prevalent Cases of HR Positive Breast Cancer in the 7MM, in Thousand (2018–2030)
Table 4 Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the 7MM, in Thousand (2018–2030)
Table 5 Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the First Line in the 7MM, in Thousand (2018–2030)
Table 6 Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the Second Line Plus in the 7MM, in Thousand (2018–2030)
Table 7 Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in the United States, in Thousand (2018–2030)
Table 8 Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the United States, in Thousand (2018–2030)
Table 9 Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in the United States, in Thousand (2018–2030)
Table 10 Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in the EU-5, in Thousand (2018–2030)
Table 11 Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the EU-5, in Thousand (2018–2030)
Table 12 Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in the EU-5, in Thousand (2018–2030)
Table 13 Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in Japan, in Thousand (2018–2030)
Table 14 Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in Japan, in Thousand (2018–2030)
Table 15 Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in Japan, in Thousand (2018–2030)
Table 16 Organizations Contributing Toward the Fight Against ESR1 Mutated Metastatic Breast Cancer
Table 17 Comparison of emerging drugs under development
Table 18 Elacestrant, Clinical Trial Description, 2021
Table 19 Palbociclib, Clinical Trial Description, 2021
Table 20 Amcenestrant, Clinical Trial Description, 2021
Table 21 Rintodestrant (G1T48), Clinical Trial Description, 2021
Table 22 SCO-120, Clinical Trial Description, 2021
Table 23 ZB716, Clinical Trial Description, 2021
Table 24 ARV-471, Clinical Trial Description, 2021
Table 25 Lasofoxifene, Clinical Trial Description, 2021
Table 26 H3B-6545, Clinical Trial Description, 2021
Table 27 Giredestrant, Clinical Trial Description, 2021
Table 28 Camizestrant (AZD9833), Clinical Trial Description, 2021
Table 29 LSZ102, Clinical Trial Description, 2021
Table 30 ZN-c5, Clinical Trial Description, 2021
Table 31 OP1250, Clinical Trial Description, 2021
Table 32 Market Size of ESR1 Mutated Metastatic Breast Cancer in the 7MM in USD Million (2018–2030)
Table 33 Market Size of ESR1 Mutated Metastatic Breast Cancer by First-line of Therapies in the 7MM, in USD Million (2018–2030)
Table 34 Market Size of ESR1 Mutated Metastatic Breast Cancer by Second-line Plus of Therapies in the 7MM, in USD Million (2018–2030)
Table 35 Key Market Forecast Assumptions for Elacestrant
Table 36 Key Market Forecast Assumptions for Lasofoxifene in combination with abemaciclib
Table 37 Key Market Forecast Assumptions for Amcenestrant alone and in combination with Palbociclib
Table 38 Key Market Forecast Assumptions for Camizestrant (AZD9833) in combination with Palbociclib
Table 39 Key Market Forecast Assumptions for Giredestrant in combination with Palbociclib
Table 40 Market Size of ESR1 Mutated Metastatic Breast Cancer in the US, in USD Million (2018–2030)
Table 41 Market Size of ESR1 Mutated Metastatic Breast Cancer by First-line of Therapies in the United States, in USD Million (2018–2030)
Table 42 Market Size of ESR1 Mutated Metastatic Breast Cancer by Second-line Plus of Therapies in the United States, in USD Million (2018–2030)
Table 43 Market Size of ESR1 Mutated Metastatic Breast Cancer in the EU5, USD Million (2018–2030)
Table 44 Market Size of ESR1 Mutated Metastatic Breast Cancer by First-line of Therapies in EU-5, in USD Million (2018–2030)
Table 45 Market Size of ESR1 Mutated Metastatic Breast Cancer by Second-line Plus of Therapies in EU-5, in USD Million (2018–2030)
Table 46 Market Size of ESR1 Mutated Metastatic Breast Cancer in Japan, in USD Million (2018–2030)
Table 47 Market Size of ESR1 Mutated Metastatic Breast Cancer by First-line of Therapies in Japan, in USD Million (2018–2030)
Table 48 Market Size of ESR1 Mutated Metastatic Breast Cancer by Second-line Plus of Therapies in Japan, in USD Million (2018–2030)